Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: skin disorder therapeutics - Azitra/Bayer

Next Previous
X
Search
Drug Profile

Research programme: skin disorder therapeutics - Azitra/Bayer

Latest Information Update: 14 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Azitra
  • Developer Azitra; Bayer
  • Class Bacteria; Skin disorder therapies
  • Mechanism of Action Bacteria replacements; Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Skin disorders

Most Recent Events

  • 15 Aug 2023 PQC feedbacks incorporated. 9396361- New profile created on the basis of agreement mentioned in the MR. Checked on pipeline- the deal was created in December 2019. Found discarded MR- 9283765. The profile and deal created on the basis of previous MR and website information. Discussed with SME for confirmation of new RP
  • 31 Jul 2023 Azitra has patent protection for treating atopic dermatitis with recombinant organisms
  • 10 Jan 2020 Azirta and Bayer agree to co-develop skin disorder theapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top